Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP)
$13.2400
+0.0800 ( +1.30% ) 95.8K
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company'sĀ development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Market Data
Open
$13.2400
Previous close
$13.1600
Volume
95.8K
Market cap
$156.14M
Day range
$12.7070 - $13.4690
52 week range
$5.3000 - $61.9000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
pre | Proxies and info statements | 5 | Mar 22, 2024 |
10-k/a | Quarterly Reports | 13 | Mar 20, 2024 |
8-k | 8K-related | 11 | Mar 20, 2024 |
8-k | 8K-related | 13 | Mar 12, 2024 |
10-k | Annual reports | 109 | Mar 12, 2024 |
4 | Insider transactions | 1 | Mar 11, 2024 |
4 | Insider transactions | 2 | Feb 29, 2024 |
3 | Insider transactions | 2 | Feb 29, 2024 |
4 | Insider transactions | 1 | Feb 14, 2024 |
4 | Insider transactions | 1 | Feb 14, 2024 |